228
Participants
Start Date
July 8, 2021
Primary Completion Date
July 25, 2024
Study Completion Date
August 7, 2024
Lumateperone 42 mg
Lumateperone 42 mg capsules administered orally, once daily.
Placebo
Matching capsules administered orally, once daily.
Clinical Site, Novi Iskar
Clinical Site, Sofia
Clinical Site, Vratsa
Clinical Site, Plovdiv
Clinical Site, Veliko Tarnovo
Clinical Site, Tserova Koria
Clinical Site, Lovech
Clinical Site, Pleven
Clinical Site, Kazanlak
Clinical Site, Kardzhali
Clinical Site, Rousse
Clinical Site, Targovishte
Clinical Site, Burgas
Clinical Site, Tsarev Brod
Clinical site, Belgrade
Clinical Site, Novi Kneževac
Clinical Site, Kovin
Clinical Site, Atlanta
Clinical Site, Miami Lakes
Clinical Site, Hollywood
Clinical Site, Oakland Park
Clinical Site, Kragujevac
Clinical Site, North Canton
Clinical Site, Chicago
Clinical Site, St Louis
Clinical Site, Little Rock
Clinical Site, Richardson
Clinical Site, DeSoto
Clinical Site, Austin
Clinical Site, Las Vegas
Clinical Site, Culver City
Clinical Site, Cerritos
Clinical Site, Montclair
Clinical Site, Lemon Grove
Clinical Site, Garden Grove
Clinical Site, Orange
Clinical Site, Tuszyn
Clinical Site, Bellflower
Clinical Site, Boston
Clinical Site, Berlin
Clinical Site, Gdansk
Clinical Site, Gdansk
Clinical Site, Gorlice
Lead Sponsor
Intra-Cellular Therapies, Inc.
INDUSTRY